Format
Sort by
Items per page

Send to

Choose Destination

Best matches for drug development and PET imaging and review:

Search results

Items: 1 to 20 of 994

1.

Journey of 2'-deoxy-2'-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU): from Antiviral Drug to PET Imaging Agent.

Alauddin MM.

Curr Med Chem. 2017 Nov 29. doi: 10.2174/0929867325666171129125217. [Epub ahead of print]

PMID:
29189119
2.

Posterior reversible encephalopathy syndrome possibly induced by pemetrexed maintenance therapy for lung cancer: a case report and literature review.

Smets GJ, Loyson T, Van Paesschen W, Demaerel P, Nackaerts K.

Acta Clin Belg. 2017 Nov 24:1-7. doi: 10.1080/17843286.2017.1403103. [Epub ahead of print]

PMID:
29173113
3.

Microdosing, isotopic labeling, radiotracers and metabolomics: relevance in drug discovery, development and safety.

Wotherspoon AT, Safavi-Naeini M, Banati RB.

Bioanalysis. 2017 Dec;9(23):1913-1933. doi: 10.4155/bio-2017-0137. Epub 2017 Nov 24.

PMID:
29171759
4.

Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future.

Reilly KM, Kim A, Blakely J, Ferner RE, Gutmann DH, Legius E, Miettinen MM, Randall RL, Ratner N, Jumbé NL, Bakker A, Viskochil D, Widemann BC, Stewart DR.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx124. Review.

PMID:
29117388
5.

Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung.

Rodvold KA, Hope WW, Boyd SE.

Curr Opin Pharmacol. 2017 Oct 30;36:114-123. doi: 10.1016/j.coph.2017.09.019. [Epub ahead of print] Review.

PMID:
29096171
6.

Multimodal nanoparticle imaging agents: design and applications.

Burke BP, Cawthorne C, Archibald SJ.

Philos Trans A Math Phys Eng Sci. 2017 Nov 28;375(2107). pii: 20170261. doi: 10.1098/rsta.2017.0261. Review.

PMID:
29038384
7.

New perspectives of Alzheimer disease diagnosis - the most popular and future methods.

Pietrzak K, Czarnecka K, Ikiciuk-Olasik EM, Szymański P.

Med Chem. 2017 Oct 2. doi: 10.2174/1573406413666171002120847. [Epub ahead of print]

PMID:
28969570
8.

Development of Antibody-Drug Conjugates Using DDS and Molecular Imaging.

Yasunaga M, Manabe S, Tsuji A, Furuta M, Ogata K, Koga Y, Saga T, Matsumura Y.

Bioengineering (Basel). 2017 Sep 17;4(3). pii: E78. doi: 10.3390/bioengineering4030078. Review.

9.

Fluorinated nucleosides as an important class of anticancer and antiviral agents.

Cavaliere A, Probst KC, Westwell AD, Slusarczyk M.

Future Med Chem. 2017 Oct;9(15):1809-1833. doi: 10.4155/fmc-2017-0095. Epub 2017 Sep 20. Review.

PMID:
28929804
10.

Dementia -- Caring, Ethics, Ethnical and Economical Aspects: A Systematic Review [Internet].

Swedish Council on Health Technology Assessment.

Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 Jun.

11.

Nanoparticles for SPECT and PET imaging: towards personalized medicine and theranostics.

Polyak A, Ross TL.

Curr Med Chem. 2017 Aug 29. doi: 10.2174/0929867324666170830095553. [Epub ahead of print]

PMID:
28875837
12.

The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review.

Fernandes RS, de Aguiar Ferreira C, Soares DCF, Maffione AM, Townsend DM, Rubello D, de Barros ALB.

Biomed Pharmacother. 2017 Nov;95:469-476. doi: 10.1016/j.biopha.2017.08.079. Epub 2017 Sep 12. Review.

PMID:
28865367
13.

Theranostics Using Antibodies and Antibody-Related Therapeutics.

Moek KL, Giesen D, Kok IC, de Groot DJA, Jalving M, Fehrmann RSN, Lub-de Hooge MN, Brouwers AH, de Vries EGE.

J Nucl Med. 2017 Sep;58(Suppl 2):83S-90S. doi: 10.2967/jnumed.116.186940. Review.

PMID:
28864618
14.

Somatostatin Receptor Antagonists for Imaging and Therapy.

Fani M, Nicolas GP, Wild D.

J Nucl Med. 2017 Sep;58(Suppl 2):61S-66S. doi: 10.2967/jnumed.116.186783. Review.

PMID:
28864614
15.

Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers.

Kopka K, Benešová M, Bařinka C, Haberkorn U, Babich J.

J Nucl Med. 2017 Sep;58(Suppl 2):17S-26S. doi: 10.2967/jnumed.116.186775. Review.

PMID:
28864607
16.

Therapeutic Potential of Selectively Targeting the α2C-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective.

Uys MM, Shahid M, Harvey BH.

Front Psychiatry. 2017 Aug 14;8:144. doi: 10.3389/fpsyt.2017.00144. eCollection 2017. Review.

17.

Objective methods for the assessment of the spinal and supraspinal effects of opioids.

Fischer IW, Hansen TM, Lelic D, Brokjaer A, Frøkjær J, Christrup LL, Olesen AE.

Scand J Pain. 2017 Jan;14:15-24. doi: 10.1016/j.sjpain.2016.10.001. Epub 2016 Nov 1. Review.

PMID:
28850426
18.

The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice.

Banerjee G, Carare R, Cordonnier C, Greenberg SM, Schneider JA, Smith EE, Buchem MV, Grond JV, Verbeek MM, Werring DJ.

J Neurol Neurosurg Psychiatry. 2017 Nov;88(11):982-994. doi: 10.1136/jnnp-2016-314697. Epub 2017 Aug 26. Review.

19.

Small Molecule PET Tracers for Transporter Imaging.

Kilbourn MR.

Semin Nucl Med. 2017 Sep;47(5):536-552. doi: 10.1053/j.semnuclmed.2017.05.005. Epub 2017 Jul 5. Review.

PMID:
28826525
20.

Small Molecule PET Tracers in Drug Discovery.

Donnelly DJ.

Semin Nucl Med. 2017 Sep;47(5):454-460. doi: 10.1053/j.semnuclmed.2017.05.006. Review.

PMID:
28826520

Supplemental Content

Loading ...
Support Center